What's new? Log in Free sign up

Charles River Laboratories International (CRL) News and press releases

Company Profile

News

From Benzinga Pro

Charles River Laboratories, AbbVie, Star Bulk Carriers And This Big Bank Are CNBC's 'Final Trades'

News, Top Stories, Markets, Media, Trading Ideas

On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said Charles River Laboratories International, Inc. (NYSE: CRL) is trading at 20 time

This Favorable Sign Appears On Charles River's Chart

Markets, Movers, Trading Ideas

Charles River And Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance

Charles River Laboratories International, Inc. (NYSE:CRL) and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector

What Does Charles River's Debt Look Like?

News, Intraday Update, Markets

Over the past three months, shares of Charles River Inc. (NYSE:CRL) increased by 16.70%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.

Jefferies Downgrades Charles River to Hold

News, Downgrades, Analyst Ratings

Jefferies analyst David Windley downgrades Charles River (NYSE:CRL) from Buy to Hold.

Baird Maintains Outperform on Charles River, Raises Price Target to $285

News, Price Target, Analyst Ratings

Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $275 to $285.

Analyst Ratings for Charles River

Analyst Ratings

Over the past 3 months, 5 analysts have published their opinion on Charles River (NYSE:CRL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

JP Morgan Maintains Overweight on Charles River, Lowers Price Target to $275

News, Price Target, Analyst Ratings

JP Morgan analyst Tycho Peterson maintains Charles River (NYSE:CRL) with a Overweight and lowers the price target from $280 to $275.

Credit Suisse Maintains Outperform on Charles River, Lowers Price Target to $280

News, Price Target, Analyst Ratings

Credit Suisse analyst Dan Leonard maintains Charles River (NYSE:CRL) with a Outperform and lowers the price target from $285 to $280.

Morgan Stanley Maintains Equal-Weight on Charles River, Lowers Price Target to $241

News, Price Target, Analyst Ratings

Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Equal-Weight and lowers the price target from $250 to $241.

Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.

United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session.

Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.

Charles River: Q3 Earnings Insights

Charles River (NYSE:CRL) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Charles River beat estimated earnings by 5.2%, reporting an EPS of $2.63 versus an estimate of $2.5.

Charles River Q3 Adj EPS $2.63 Beats $2.50 Estimate, Sales $989.20M Beat $970.37M Estimate

Charles River (NYSE:CRL) reported adj quarterly earnings of $2.63 per share which beat the analyst consensus estimate of $2.50 by 5.2 percent. This is a 2.59 percent decrease over earnings of $2.70 per share from the

Earnings Scheduled For November 2, 2022

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.

Press releases

From Benzinga Pro

Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products

This initial launch includes the CliniPrime Fresh Leukopak, supporting clinical trials and commercialization of advanced therapies Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of

Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs

Company will launch the eXpDNA Platform at Phacilitate Advanced Therapies Week Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of its eXpDNA™ plasmid platform, established

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, at 10:30 a.m. PST (1:30 p.m. EST). Management

Arlington Capital Partners Announces the Acquisition of AVS Bio

Arlington Capital Partners ("Arlington"), a Washington, DC-area private equity firm, announced today it has acquired Charles River Laboratories' (NYSE:CRL) Avian Vaccine Services business to form a new company, AVS Bio

Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors

Charles River Laboratories International, Inc. (NYSE:CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, to its Board

Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection

Next generation robotic endotoxin testing system boosts manufacturing productivity in the lab Charles River Laboratories International, Inc. (NYSE:CRL) launches the Endosafe® Nexus 200™, expanding its

Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program

Charles River Laboratories International, Inc. (NYSE:CRL) recently opened the first Charles River Accelerator and Development Lab (CRADL®) location in Chicago, expanding contract vivarium space for the

Clinical Laboratory Services Market Size to Worth Around US$ 307.3 Billion by 2027 – Exclusive Report by IMARC Group

News, Press Releases

"Clinical Laboratory Services Market Report"Global clinical laboratory services are an essential part of the healthcare industry as they are used for the evaluation, diagnosis, treatment, prevention and management of

Charles River Laboratories Demonstrates Excellence in Advanced Modalities at Neuroscience 2022

Charles River Laboratories International, Inc. (NYSE:CRL) today announced that its team of neuroscience drug discovery experts will present 23 scientific posters, both independently and collaboratively with clients, at

Microbial Identification Market to Reach US$ 7.32 Billion by 2027 | IMARC Group

News, Press Releases

"Microbial Identification Market Report 2022-2027"The global microbial identification market size reached US$ 3.57 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 7.32 Billion by

Oncology Based In-vivo CRO Market Report 2022 | Share, Trends 2027

News, Press Releases

"Oncology Based In-vivo CRO Market Report 2022-2027"The global oncology based in-vivo CRO market reached a value of US$ 1.05 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.69

Charles River Laboratories Announces Third-Quarter 2022 Results

– Third-Quarter Revenue of $989.2 Million – – Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 – – Narrows 2022 Revenue Growth and Earnings Per Share Guidance – – Announces